PBYI
Puma Biotechnology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PBYI
Puma Biotechnology, Inc.
A biopharmaceutical company that develops drug candidates for the treatment of cancer
Biological Technology
04/27/2007
01/03/2017
NASDAQ Stock Exchange
172
12-31
Common stock
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA 90024
--
Puma Biotechnology, Inc., a Delaware corporation, was founded on April 27, 2007. The company is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve patient outcomes. The company is currently commercializing NERLYNX, an oral version of nelatinib for the treatment of HER2-positive breast cancer.
Earnings Call
Q2/2025
Estimate EPS0.07
Actual EPS0.15
Estimate Revenue52.00M
Actual Revenue52.40M
Puma Biotechnology's Q2 2025: Key Contradictions in Alisertib Strategy, In-Licensing, and Sales Growth
Aug 07,2025 09:03
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PBYI has released its 2025 Q3 earnings. EPS was reported at 0.21, versus the expected 0.09, beating expectations. The chart below visualizes how PBYI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PBYI has released its 2025 Q3 earnings report, with revenue of 54.48M, reflecting a YoY change of -32.36%, and net profit of 8.84M, showing a YoY change of -56.47%. The Sankey diagram below clearly presents PBYI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
